Navigation Links
Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
Date:4/2/2013

rials mid-year."

About Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS) is a chronic, very rare, life-threatening disease. The condition has the hallmarks of a thrombotic microangiopathy and manifests as hemolytic anemia, thrombocytopenia and renal impairment. aHUS differs from HUS in that an infectious etiology, i.e., E. coli or streptococcal infection, is absent. Dysregulation of the complement system lies at the heart of aHUS pathogenesis, and genetic abnormalities in complement genes have been identified in greater than 60 percent of all aHUS patients. It is thought that certain precipitating factors are needed to trigger aHUS in a genetically predisposed individual. Many of the potential precipitating factors are linked to endothelial cell activation, stress or injury; all of these processes activate the lectin pathway. If untreated, most aHUS patients die or develop end-stage renal disease within one year of diagnosis. Current treatment options include plasma therapy and eculizumab, which have limitations in terms of feasibility, safety and patient convenience.

About Omeros' MASP-2 Program

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. MASP-2 appears to be unique to, and required for the function of, one of the principal complement activation pathways, known as the lectin pathway. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection, and its abnormal function is associated with a wide range of autoimmune disorders. MASP-2 is
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 Zimmer Holdings, Inc. ... new mobile app designed to serve as a feature-rich resource ... product. For those experiencing knee pain, the ... about the causes of knee pain and helps them understand ... a safe and simple non-surgical treatment option. For those who ...
(Date:3/26/2015)... , March 26, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... received a patent acceptance notice from the Israeli patent ... to prevent or reduce tissue damage caused by an ... when cardiac vessels are opened after a blockage causing ... stroke victims. Damage can be caused to ...
(Date:3/26/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a leading ... healthcare industry in the United States ... secured a new $45.0 million credit facility with JPMorgan Chase ... facility with its prior lender group.  Effective ... senior secured credit agreement comprised of a $10.0 million asset-based ...
Breaking Medicine Technology:Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 2InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 4
... NEW YORK, Feb. 15, 2011 Reportlinker.com ... is available in its catalogue: ... CE countries 2011 - Comparative analysis, reimbursement ... http://www.reportlinker.com/p0395681/Generic-and-innovative-drug-market-in-CE-countries-2011---Comparative-analysis-reimbursement-policies-and-development-forecasts-for-2011-2013 ...
... 15, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... a conference call and a live Internet webcast along with ... a.m. ET (7:00 a.m. PT) to discuss results for the ... number to participate on this call is (877) 295-5743, confirmation ...
Cached Medicine Technology:Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013 2Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:3/26/2015)... (PRWEB) March 26, 2015 The American College ... be on the topics of the DAOM Program as well ... Program Overview Webinar will be hosted by Dr. Carla Wilson, ... the next steps on how to prepare for the spring ... March 25, March 27, April 1 and April 3. Attendees ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Baruch ... new team of nationally renowned scientists to focus exclusively ... a move that nearly triples its research capacity and ... solely on hepatitis B and liver cancer in the ... Block, Jinhong Chang, Ju Tao Guo and Ying-Hsiu Su ...
(Date:3/26/2015)... 26, 2015 Visiting Nurse Association ... 18th annual gala fundraiser, Lighting the Way, Brightening the ... at The Madison Hotel in Morristown, NJ. , ... by renowned musician Rio Clemente, delightful cuisine, an extensive ... Dave Hertzel. Additionally, two prestigious awards will be presented ...
(Date:3/26/2015)... NY (PRWEB) March 26, 2015 ... its 30th “Introduction to Hyperbaric Medicine” course, which ... Medical Society (UHMS) and the National Board of ... provides the 40-hour course 4 times a year ... around the NY tri-state region; registration is available ...
(Date:3/26/2015)... March 26, 2015 On March 5, ... Matthews is out for the season with a torn ... while the Trail Blazers were competing against Dallas, and ... specialist, Izzy Silva, M.D., who has treated many ... and whether it could be prevented. , "Part ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming Webinars 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 3Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 4Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4
... the U.S. Department of Agriculture found that a compound in ... compound, pterostilbene, is a potent antioxidant that could be developed ... effects than some commercial drugs that are currently used to ... cause of cancer death in the United States. ...
... discovered by researchers at Weill Cornell Medical College could prove ... ,The compound, called SS31, is able to cross the ... to stroke-related tissue damage. ,"In our experiments, we ... stroke led to a much smaller area of brain tissue ...
... specially developed proteins could make our bodies more resistant ... ,Steaks and chicken fillets laced with some ... against oxidation – oxidation is considered a major cause ... Shchepinov, a former Oxford University scientist, has found ...
... University of Wisconsin-Madison claim that they can efficiently seek ... cells//. This is very similar to the Nature's way ... ,The new tumor targeting strategy, presented today (March ... Chemical Society, cleverly harnesses one of the body's natural ...
... wisdom, in order to deal with teenage pregnancies and ... ,Improving pupil-teacher relationships and raising a teenager’s self-confidence ... will do the trick, say the researchers. In this ... newer ones such as focusing on sexual risks ,and ...
... the omega-3 fatty acids docosahexaenoic acid (DHA) successfully reduced ... trial, backing up previous results with higher doses. // ... which is likely to be of clinical significance with ... subjects," wrote lead author Hannah Theobald from King's College ...
Cached Medicine News:Health News:Eat Berries, Prevent Colon Cancer 2Health News:Eat Berries, Prevent Colon Cancer 3Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Tumors Targeted Naturally 2Health News:Tumors Targeted Naturally 3Health News:'School Sermons' Need a Comeback 2Health News:Low-dose Omega-3 Linked to Lower Blood Pressure 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: